These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 843872)

  • 61. [Clinical remission in Cushing's disease through treatment with sodium valproate and bromocriptine].
    García Rojas JF; Mangas Rojas A; Barba Chacón A; García Osle M; Zamora Madaria E
    Rev Clin Esp; 1991 Jan; 188(1):37-40. PubMed ID: 2063025
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Medical treatment of Cushing syndrome].
    Mantero F; Sonino N
    Minerva Endocrinol; 1990; 15(1):17-21. PubMed ID: 2274010
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cushing's syndrome.
    McPherson HT
    Urol Clin North Am; 1977 Jun; 4(2):211-26. PubMed ID: 197679
    [No Abstract]   [Full Text] [Related]  

  • 64. Failure of cyprohepatdine to inhibit vasopressin-stimulated cortisol release in a patient with Cushing's disease.
    George WF; Husain M; Lock JP; Katz FH
    Horm Res; 1976; 7(4-5):308-12. PubMed ID: 1017793
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A cyproheptadine-reversible defect in ACTH control persisting after removal of the pituitary tumor in Cushing's disease.
    Lankford HV; Tucker HS; Blackard WG
    N Engl J Med; 1981 Nov; 305(21):1244-8. PubMed ID: 6270557
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Drugs in the medical treatment of Cushing's syndrome.
    Schteingart DE
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland.
    Croughs RJ; Koppeschaar HP; van't Verlaat JW; McNicol AM
    J Clin Endocrinol Metab; 1989 Feb; 68(2):495-8. PubMed ID: 2537335
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Physiopathology of Cushing's disease.
    Krieger DT
    Endocr Rev; 1983; 4(1):22-43. PubMed ID: 6131818
    [No Abstract]   [Full Text] [Related]  

  • 69. Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease.
    Suda T; Tozawa F; Mouri T; Sasaki A; Shibasaki T; Demura H; Shizume K
    J Clin Endocrinol Metab; 1983 Jun; 56(6):1094-9. PubMed ID: 6302123
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cushing's disease: megadose dexamethasone suppression in a case refractory to medical therapy.
    Warren SE; Westbie DK; Daly R; Bower RH
    South Med J; 1979 Apr; 72(4):412-4. PubMed ID: 219547
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Criteria for the selection of drugs for the pathogenetic treatment of Itsenko-Cushing disease].
    Slavnov VN; Luchitskiĭ EV; Cheban AK
    Ter Arkh; 1985; 57(12):36-9. PubMed ID: 3003946
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Drug and radiotherapy of pituitary tumors].
    Yoshida H; Takeda F; Kinouchi T; Shimizu N
    Nihon Rinsho; 1986 Mar; 44(3):659-66. PubMed ID: 3016373
    [No Abstract]   [Full Text] [Related]  

  • 73. [Drug therapy of pituitary tumors].
    Kato Y
    Nihon Naika Gakkai Zasshi; 1991 Mar; 80(3):368-72. PubMed ID: 1856549
    [No Abstract]   [Full Text] [Related]  

  • 74. [Dynamics of secretion of hypothalamo-hypophyseal system hormones in Itsenko-Cushing disease as affected by combination therapy].
    Slavnov VN; Valueva GV; Luchitskiĭ EV; Komissarenko IV; Cheban AK
    Probl Endokrinol (Mosk); 1983; 29(6):28-32. PubMed ID: 6140677
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Evaluation of the treatment of Cushing's syndrome using ketoconazole].
    Conget JI; Halperin I; Vendrell J; Ferrer J; Martínez-Osaba MJ; Esmatjes E; Vilardell E
    Med Clin (Barc); 1989 Nov; 93(14):531-4. PubMed ID: 2695699
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Treatment of Cushing's syndrome].
    Wajchenberg BL; Pereira VG; Schnaider J; Pupo AA; Liberman B; Quintão ER
    Rev Assoc Med Bras; 1966 May; 12(5):205-13. PubMed ID: 4300817
    [No Abstract]   [Full Text] [Related]  

  • 77. Primary therapy for Cushing's disease with metyrapone.
    Dickstein G; Lahav M; Shen-Orr Z; Edoute Y; Barzilai D
    JAMA; 1986 Mar; 255(9):1167-9. PubMed ID: 3003415
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Medical treatment for Cushing's syndrome].
    Nishikawa T; Saito J; Omura M
    Nihon Rinsho; 2008 Jan; 66(1):186-91. PubMed ID: 18186263
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Changes in the secretion of the hormones of the hypothalamo-hypophyseo-adrenal system in Itsenko-Cushing disease under the influence of insulin-induced hypoglycemia and thyroliberin].
    Slavnov VN; Luchitskiĭ EV
    Vrach Delo; 1990 Mar; (3):72-5. PubMed ID: 2164280
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Personality characteristics and quality of life in patients treated for Cushing's syndrome.
    Sonino N; Bonnini S; Fallo F; Boscaro M; Fava GA
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):314-8. PubMed ID: 16487442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.